首页> 外文期刊>Current organic chemistry >Bridging the Gap Between Chemistry and Biotechnology - Large Molecules with Potential, How Could Biotechnology Complement Chemistry?
【24h】

Bridging the Gap Between Chemistry and Biotechnology - Large Molecules with Potential, How Could Biotechnology Complement Chemistry?

机译:弥合化学与生物技术之间的鸿沟-具有潜力的大分子,生物技术将如何补充化学?

获取原文
获取原文并翻译 | 示例
       

摘要

Chemical synthesis of small molecules is well established and enzyme-mediated chemical synthesis is a growing area, with great potential to be expanded in the future. The recombinant production of proteins has become routine. But molecules of intermediate size remain generally much more difficult to be produced in a sustainable way. Oligopeptides, oligosaccharides and oligonucleotides are three areas orphaned by biotechnology. The industrial manufacturing of all three oligomer types uses almost exclusively chemical synthesis, although conceptually biotechnological methods exist. This review gives an introduction to the market and applications of all three product classes as well as manufacturing options. The future situation could become difficult for all three, but particularly rapidly for peptides, where a number of products are discussed for markets other than the parenteral (injectable) pharmaceuticals. Cost and e-factors of actual chemical methods are by far ?oo high to allow such commercial application, and ecologically and economically sustainable manufacturing methods are urgently needed. The review also shows that similar problems may arise for future pharmaceutical oligonucleotide and oligosaccharide drug products, as aspects of sustainability and cost of goods may significantly limit their broad availability and thereby their potential for commercial success.
机译:小分子的化学合成已经建立,酶介导的化学合成是一个发展中的领域,在未来有很大的发展潜力。蛋白质的重组生产已成为常规。但是中等大小的分子通常仍然很难以可持续的方式生产。寡肽,寡糖和寡核苷酸是生物技术孤立的三个领域。尽管在概念上存在生物技术方法,但所有这三种低聚物类型的工业生产几乎仅使用化学合成。这篇综述介绍了这三种产品类别的市场和应用以及制造选项。三者的未来情况可能会变得困难,但对于肽来说尤其会迅速,在肽中,除了肠胃外(注射剂)药物外,还将针对市场讨论许多产品。迄今为止,实际化学方法的成本和电子因素很高,以允许这种商业应用,并且迫切需要生态上和经济上可持续的制造方法。审查还表明,未来的药物寡核苷酸和寡糖药物产品可能会出现类似的问题,因为可持续性和商品成本方面可能会大大限制其广泛的可获得性,从而限制其商业成功的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号